[Interleukin-34: a key molecule in the tumor microenvironment].

Area of Science:

• Oncology
• Immunology
• Cancer Biology

Background:

• The tumor microenvironment (TME) often exhibits immune resistance, hindering effective cancer treatment.
• Cancer immunotherapy, including checkpoint inhibitors (PD-1, CTLA-4), has revolutionized treatment but faces response limitations.
• Macrophages are abundant in tumors and frequently adopt immunosuppressive phenotypes, making them potential therapeutic targets.

Purpose of the Study:

• To comprehensively review the multifaceted roles of Interleukin-34 (IL-34) within the tumor microenvironment (TME).
• To highlight IL-34 as a key factor influencing macrophage polarization towards immunosuppressive states.
• To explore the potential of targeting IL-34 as a novel therapeutic strategy in cancer treatment.

Main Methods:

• Literature review synthesizing current research on IL-34 and its functions in cancer.
• Analysis of studies investigating IL-34 expression in various cancer types.
• Examination of the mechanisms by which IL-34 influences macrophage behavior and the TME.

Main Results:

• IL-34 is expressed in diverse cancer cells and significantly contributes to the immunosuppressive TME.
• IL-34 actively biases macrophages towards immunosuppressive phenotypes, promoting immune evasion.
• IL-34 plays critical roles in multiple facets of tumor progression and immune modulation.

Conclusions:

• IL-34 is a crucial mediator of immune suppression within the tumor microenvironment.
• Targeting IL-34 presents a promising avenue for developing novel cancer immunotherapies.
• Further research into IL-34's mechanisms could lead to improved treatment strategies for non-responsive patients.